Register
Login:
Share:
Email Facebook Twitter

#AST: Board changes and new strategy for Ascent as Hutchinson looks at new projects Watch Here

#AST: Board changes and new strategy for Ascent as Hutchinson looks at new projects
EXCLUSIVE: Petro Matad announce fully funded 4 well Mongolia campaign




Share Price Information for Sareum (SAR)


Share Price: 0.575Bid: 0.55Ask: 0.60Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 9.09%Open: 0.575High: 0.575Low: 0.575Yesterday’s Close: 0.575

Sareum Holdings Plc Ord 0.025P

Sareum is listed in the FTSE AIM All-Share
Sareum is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
0.575
Share Price SpacerBid
0.55
Share Price SpacerAsk
0.60
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
3,091,697
Share Price SpacerOpen
0.575
Share Price SpacerHigh
0.575
Share Price SpacerLow
0.575
Share Price SpacerClose
0.575
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 2,875.99m £16.54m 300,000

52 Week High 1.03 52 Week High Date 27-FEB-2018
52 Week Low 0.48 52 Week Low Date 27-DEC-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
5 2,406,614 338,298 -11.500 -0.05 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

16-Jan-19
16:23:27
0.5875
338,298
Buy* 
0.55
0.60
1,988
Trade Type:
Ordinary

16-Jan-19
14:34:24
0.575
346,785
Sell* 
0.55
0.60
1,994
Trade Type:
Ordinary

16-Jan-19
14:15:51
0.5732
1,000,000
Sell* 
0.55
0.60
5,732
Trade Type:
Ordinary




View more Sareum trades >>

Directors Deals for Sareum (SAR)
Trade DateActionNotifierPriceCurrencyAmountHolding
08-Mar-17Buy
Trade Notifier Information for Sareum Holdings
Stephen Parker held the position of Non-Executive Chairman at Sareum Holdings at the time of this trade.
 Stephen Parker
0.95GBX461,949674272
08-Mar-17Buy
Trade Notifier Information for Sareum Holdings
Stephen Parker held the position of Non-Executive Chairman at Sareum Holdings at the time of this trade.
 Stephen Parker
0.95GBX674,272674272
07-Mar-11Sell
Trade Notifier Information for Sareum Holdings
Timothy J Mitchell held the position of CEO at Sareum Holdings at the time of this trade.
 Timothy J Mitchell
2.45GBX250,0000
View more Sareum directors dealings >>


Stoney40
Posts: 921
Opinion:No Opinion
Price:0.575
RE: Impact on life
Today 06:53
Great find Num4......much appreciated if you could share the source?

We must quickly becoming a serious hot target. Time will tell (some of LTHs will hang me for that comment) but best in class will be worth unspeakable value.

GLA
cesare1221
Posts: 9
Opinion:No Opinion
Price:0.575
RE: Impact on life
Today 06:42
Thanks Num4. Would you post the link, please?
Num4
Posts: 1,367
Opinion:No Opinion
Price:0.575
Impact on life
Today 00:07
All,
Whilst decided which avenue to explore for further research I delved a little into SRA737 trials. This is when it really hits home about our investment, I found a diary of someone on the SRA737 trial, fully updated from start to current cycle 4 treatment. They are on a break and due CT scan end of this month. Whilst they experienced sickness at start taking 500mg across 5x 100mg tablets they have a very positive story to tell. In short, after 56days, no progression of disease, bones re-calcifying themselves, nausea is under control, mentions stopping the clock on cancer.
Next set of results end of Jan.
sadoldgit
Posts: 567
Premium Chat Member
Opinion:No Opinion
Price:0.575
Re re Com on bod.
Wed 10:43
I don't think you are far out there JT. 2 directors taken on a few months ago and it It a code of practice not law as such as these 2 are not share holders do not have bias as does a share holder director. I remember talking to a retired solicitor about 3 years ago about company takeovers and deals (Poor old Tim died cancer last year) . Tim worked in company Law and dealt with such as MOD, Marconi. Plessy and a lot of others. These deals he said do not happen overnight. 18 months to 2 years he said are about the norm. As Tim has stated previously we are in talks with various interested partners. That does not mean that is 18 months to 2 years from now.

CHk 1 looks promising, TYK 2 the same but not as far advanced with regards to development. Aurora plus FLT 3 does have issues, at the same time potential, but development stopped to divert funds elsewhere. SP may drop slightly short term as when further funding or milestone payment becomes known.

Nothing spectacular of course, but I favour TYK 2, that is not to say I do not CHK1 as far more potential than perhaps we realise. It would be nice to get an update from Sierra on this but feed back on this so far has been excellent. It cannot be hurried and unfortunately this takes time. I have been here 7 years now which is not as long as some.

Big companies are looking for best in class drugs that work, the older treatments patents are expiring, generic drugs manufactured in India are a threat to big companies financial returns. The products Sareum are developing now are the treatments of the future when proven.

Not, put much of any interest really. It is also nice a couple of Pratt posters have gone quiet too.

Regards to all

PS am slightly pissed.
JonTangle
Posts: 890
Opinion:No Opinion
Price:0.575
RE: Come on BOD
Wed 10:07
or...

It could be a further indication that they are in some form of a closed period/NDA?
View more share chat for Sareum (SAR) >>




Sareum Holdings Plc Ord 0.025P home pageWebsite: Sareum Holdings Plc Ord 0.025P
Website Description: Sareum Ltd. Structure Based Discovery



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk











Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.